Skip to main content
OpenTrials
Completed

NCT Number: NCT03560791

A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence

An analysis of Low-Dose Cat Scan(LDCT) Screenings for Lung Cancer completed within the St. Elizabeth system from January 2015 until December 2019. The study investigator, or designee(s), will retrospectively review patient encounters, collecting data related to LDCT referrals and completions. Data analysis will focus on the subsequent imaging, procedures, reviews at The Nodule Review Board and Lung Cancers diagnosed as a result of the LDCT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

St. Elizabeth Healthcare

Edgewood, Kentucky, 41017, United States

About this study

This study is a single center, minimal risk, physician initiated retrospective chart review. Potential subjects will be identified using records provided by the St. Elizabeth Healthcare Thoracic Oncology and Radiology Department. Potential subjects will be screened for eligibility. Study investigator and designees will review patient electronic medical records, extracting data related to the ordering/completion of a LDCT and interventions that occurs thereafter. Collected data will focus on dates of encounters, diagnostic imaging/procedures, and treatments. Please see Appendix A for a complete list of data points. All of the data that will be collected for study purposes will be kept confidential. This will be attained by the following: First, each enrolled subject will be assigned a study specific serial number for the database. All study documents and data collection tools will be maintained with the investigative site file in a locked cabinet in a secure location maintained by the investigator. The database will not include the patient's name or hospital medical record number. No one will have access to the database but the study principal investigator and study staff designated by the principal investigator. However, study data may be reviewed by the Institutional Review Board of record, an appointed study monitor, an internal auditor for St. Elizabeth Healthcare, and necessary regulatory authorities. The security of the database will be maintained under the direction of the principal investigator. Fourth, when the study is completed, the manuscript is published, and IRB storage document requirements have been met, the file will be permanently deleted and destroyed

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients within St Elizabeth Healthcare who are referred for and/or have completed a LDCT from January 2015-February 2018
  • >=18 years of age

Exclusion criteria

  • Patient undergoes subsequent imaging, procedures and/or treatment at a facility outside of St. Elizabeth where records are not available through EPIC

Treatment and study plan

Primary outcomes

  1. Date(s) of LDCT

    Time frame: From patient referral for LDCT to completion of screening up to 1 year

    When the patient completed the LDCT(s)

Secondary outcomes

  1. Additional Imaging caused by LDCTs

    Time frame: From patient referral through last radiographic image up to 6 years

  2. Additional Procedures caused by LDCTs

    Time frame: From evidence of concerning nodule through completion of treatment up to 6 years

  3. Adverse Events caused by LDCTs

    Time frame: From first screen through last treatment intervention for the nodule up to 6 years

Other outcomes

  1. Nodule Categories

    Time frame: From first LDCT through final LDCT up to 6 years

  2. Cancer Diagnosis

    Time frame: From detection of nodule through diagnostic pathology result up to 6 years

  3. Stage of cancer diagnosis

    Time frame: From detection of nodule through diagnostic pathology result up to 6 years

  4. Presentation in Tumor Board

    Time frame: From diagnosis of cancer through completion of treatment up to 6 years

  5. Presentation in Nodule Review Board

    Time frame: From detection of category 4 nodule through completion of screening up to 6 years

  6. Referral Date for LDCT

    Time frame: From identification of eligible patient through LDCT screen completion up to 1 year

Sponsors and collaborators

Lead sponsor

St Elizabeth Healthcare

Other

Registry information

Acronym: REACH

Important dates

Study start
2018
Primary completion
2021
Study completion
2023
First posted
Jun 18, 2018
Registry last updated
Jul 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.